AU2010256442B2 - Interlaced method for treating cancer or a precancerous condition - Google Patents

Interlaced method for treating cancer or a precancerous condition

Info

Publication number
AU2010256442B2
AU2010256442B2 AU2010256442A AU2010256442A AU2010256442B2 AU 2010256442 B2 AU2010256442 B2 AU 2010256442B2 AU 2010256442 A AU2010256442 A AU 2010256442A AU 2010256442 A AU2010256442 A AU 2010256442A AU 2010256442 B2 AU2010256442 B2 AU 2010256442B2
Authority
AU
Australia
Prior art keywords
tumor
dosage
cell cycle
phase
cancerous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010256442A
Other languages
English (en)
Other versions
AU2010256442A1 (en
Inventor
Lloyd S. Gray
Andrew J. Krouse
Joel Linden
Timothy Macdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cavion LLC
Original Assignee
Cavion LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cavion LLC filed Critical Cavion LLC
Publication of AU2010256442A1 publication Critical patent/AU2010256442A1/en
Application granted granted Critical
Publication of AU2010256442B2 publication Critical patent/AU2010256442B2/en
Assigned to CAVION LLC reassignment CAVION LLC Amend patent request/document other than specification (104) Assignors: TAU THERAPEUTICS LLC
Assigned to CAVION, INC. reassignment CAVION, INC. Request to Amend Deed and Register Assignors: CAVION LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2010256442A 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition Ceased AU2010256442B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18465809P 2009-06-05 2009-06-05
US61/184,658 2009-06-05
PCT/US2010/037437 WO2010141842A2 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition

Publications (2)

Publication Number Publication Date
AU2010256442A1 AU2010256442A1 (en) 2012-01-19
AU2010256442B2 true AU2010256442B2 (en) 2016-07-21

Family

ID=43298556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010256442A Ceased AU2010256442B2 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition

Country Status (15)

Country Link
US (2) US20120088807A1 (enExample)
EP (1) EP2437749B8 (enExample)
JP (2) JP5806210B2 (enExample)
KR (2) KR20120030112A (enExample)
CN (2) CN106177963A (enExample)
AU (1) AU2010256442B2 (enExample)
CA (1) CA2764499A1 (enExample)
DK (1) DK2437749T3 (enExample)
ES (1) ES2661216T3 (enExample)
IL (2) IL216443A (enExample)
MX (1) MX344725B (enExample)
PL (1) PL2437749T3 (enExample)
SG (3) SG176678A1 (enExample)
WO (1) WO2010141842A2 (enExample)
ZA (1) ZA201108909B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542155B1 (en) 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
SG10201601917XA (en) * 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
US11058624B2 (en) 2014-02-06 2021-07-13 The Procter And Gamble Company Hair care composition comprising cationic polymers and anionic particulates
US11642353B2 (en) 2014-02-06 2023-05-09 The Procter & Gamble Company Hair care composition comprising antidandruff agent and polyquaternium-6
CA3002831C (en) 2015-10-22 2024-04-16 Cavion, Inc. Methods for treating angelman syndrome and related disorders
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3053781A1 (en) 2017-02-15 2018-08-23 Cavion, Inc. Benzopyran and naphalene derivatives and their uses as calium channel inhibitors
CN110770221B (zh) 2017-04-26 2023-09-08 卡维昂公司 用于改善记忆和认知以及用于治疗记忆和认知障碍的方法
CA3115235A1 (en) 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US11964038B2 (en) 2018-10-04 2024-04-23 The Procter & Gamble Company Personal care composition comprising water insoluble solid organic compound
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
WO2006023883A2 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
US20060000320A1 (en) * 2004-06-30 2006-01-05 Hutton William M Ratchet wrench tool assembly for underground work and process of using
WO2006023881A2 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CN100546579C (zh) * 2006-12-30 2009-10-07 南京工业大学 替莫唑胺聚乳酸纳米微球与制剂及其制备方法
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
WO2006023883A2 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOSHIDA, J. et al. "G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells." Biochem Pharmacol. (14 December 2006) vol. 73, no. 7, page 943-953. *

Also Published As

Publication number Publication date
SG10201402863PA (en) 2014-10-30
IL216443A0 (en) 2012-02-29
US20120088807A1 (en) 2012-04-12
SG10201810806UA (en) 2019-01-30
EP2437749A2 (en) 2012-04-11
JP6159958B2 (ja) 2017-07-12
CN106177963A (zh) 2016-12-07
KR101905050B1 (ko) 2018-10-08
JP2012528890A (ja) 2012-11-15
US20180228822A1 (en) 2018-08-16
KR20120030112A (ko) 2012-03-27
ZA201108909B (en) 2013-02-27
KR20170097237A (ko) 2017-08-25
JP2016028058A (ja) 2016-02-25
EP2437749B1 (en) 2017-12-20
ES2661216T3 (es) 2018-03-28
IL248482A0 (en) 2016-12-29
EP2437749B8 (en) 2018-02-21
EP2437749A4 (en) 2013-04-17
IL248482B (en) 2020-08-31
CA2764499A1 (en) 2010-12-09
AU2010256442A1 (en) 2012-01-19
PL2437749T3 (pl) 2018-04-30
WO2010141842A2 (en) 2010-12-09
SG176678A1 (en) 2012-01-30
MX344725B (es) 2017-01-05
CN102458416A (zh) 2012-05-16
JP5806210B2 (ja) 2015-11-10
DK2437749T3 (da) 2018-01-29
MX2011012940A (es) 2012-04-20
IL216443A (en) 2016-11-30
WO2010141842A3 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
AU2010256442B2 (en) Interlaced method for treating cancer or a precancerous condition
Guise Antitumor effects of bisphosphonates: promising preclinical evidence
RU2764175C1 (ru) Бифункциональные композиции для лечения рака
Abou-Jawde et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial
JP2018087228A (ja) がんのためのグルフォスファミド組み合わせ療法
Edwards et al. A kappa opioid receptor agonist blocks bone cancer pain without altering bone loss, tumor size, or cancer cell proliferation in a mouse model of cancer-induced bone pain
US20240082177A1 (en) Use of cysteamine and derivatives thereof to suppress tumor metastases
WO2016166761A1 (en) Combination therapies and uses thereof in the treatment of cancer
CN116492320B (zh) 大果桉醛i在制备肿瘤免疫治疗增效剂中的应用
HK1168764A (en) Interlaced method for treating cancer or a precancerous condition
HK1168764B (en) Interlaced method for treating cancer or a precancerous condition
JP2015505313A (ja) 癌を治療するための併用療法
Ozkan et al. Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine
CN119235866B (zh) Sn38和az20在制备治疗脑干胶质瘤药物中的用途
WO2022123432A1 (en) Pharmaceutical compositions comprising harmine and cordycepin for use in the treatment of cancer
Petruzelka et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy—results from an expanded access programme
TW201513871A (zh) 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法
Zaniboni et al. 220 Taxol, ifospamide and carboplatin for NSCLC: A phase II study
Sørensen et al. 218 Phase II study of bi-weekly paclitaxel (P) and cisplatin (C) for non-resectable non small-cell lung cancer (NSCLC)
Arita et al. 219 Prediction of carboplatin clearance on Japanese lung cancer patients
CN111407748A (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
Ruotsalainen et al. 221 IFN-α and retinoic acid maintenance therapy for SCLC
WO2018069924A1 (en) Non-cytotoxic combination therapies and uses thereof in the treatment of cancer
MX2013004423A (es) Uso de cisteamina y derivados de la misma para suprimir metastasis de tumor.
AU2013205350A1 (en) Use Of Cysteamine And Derivatives Thereof To Surpress Tumor Metastases

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CAVION LLC

Free format text: FORMER NAME(S): TAU THERAPEUTICS LLC

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: CAVION, INC.

Free format text: FORMER NAME(S): CAVION LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired